Bipolar Maintenance Treatment: Preventing Relapse Over Time
Ukrainian Psychological Hub · October 9, 2026 · Editorial Policy
Bipolar maintenance treatment is the long-term phase of care designed to reduce the risk of future manic, hypomanic, depressive, and mixed episodes while protecting everyday functioning, physical health, and quality of life. For many people, it begins after an acute episode has improved and continues through periods when mood feels stable. Decisions are individualized according to bipolar subtype, previous episodes, response to treatment, adverse effects, and personal priorities. The NICE bipolar guideline and CANMAT/ISBD evidence update both describe maintenance as a central component of ongoing care.
A sound maintenance plan combines an evidence-based medication strategy, regular assessment, appropriate psychological support, and a practical response to early changes. Its success is measured over time: fewer or less severe episodes, manageable treatment burdens, sustained relationships and work or study, and the person's ability to participate in decisions. The National Institute of Mental Health emphasizes that long-term treatment can support meaningful recovery and improved functioning.
For additional clinical context, see Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care, Treatment for Acute Mania: Safety, Medication, and Specialist Care and Psychotherapy for Bipolar Disorder: Psychoeducation, CBT, and Family Therapy.
What Is Bipolar Maintenance Treatment?
Acute treatment addresses a current manic, hypomanic, or depressive episode. Continuation care consolidates improvement during the months immediately after symptoms diminish. Maintenance treatment aims to prevent future episodes and attend to residual symptoms and functional recovery. Clinicians may use these phase labels differently, and the boundaries can overlap; their practical value is in distinguishing the immediate need to stabilize an episode from the longer-term task of lowering recurrence risk. The 2025 clinical practice guideline explains this phase model, while VA/DoD guidance separates treatment and prevention recommendations by mood polarity.
In research, relapse sometimes means a return of symptoms from the same episode before sustained recovery, while recurrence denotes a new episode after recovery. Clinical publications do not always use these terms identically. A prevention plan covers both possibilities. It also responds to subthreshold symptoms, disrupted sleep, substance use, medication problems, and functional difficulties that can precede a full episode.
Why treatment continues when someone feels well
Stable mood may reflect effective treatment, natural periods of remission, or both. Feeling well at a single point does not demonstrate that future risk has disappeared. Bipolar disorder varies widely between people: some experience infrequent episodes, others have repeated mood episodes or persistent symptoms between episodes. Treatment decisions therefore rely on longitudinal history and shared clinical assessment rather than the absence of symptoms during a good week or month. This long-term framework is consistent with NIMH guidance.
Who Needs Long-Term Relapse Prevention?
Maintenance care is routinely considered after bipolar I mania and for recurrent bipolar depression or clinically significant hypomanic and depressive episodes. It is especially important when earlier episodes involved hospitalization, psychosis, impaired judgment, substantial functional losses, suicidality, frequent recurrence, or severe sleep disruption. Clinicians also consider the person's age, medical conditions, support system, occupational demands, reproductive plans, and how effective or tolerable previous treatments were. NICE recommendation 1.7.1 calls for a detailed discussion of these issues after each manic or depressive episode.
Bipolar I and bipolar II require individualized decisions
Bipolar I disorder includes at least one manic episode; bipolar II disorder involves hypomania and major depressive episodes without a history of full mania. Bipolar II can involve severe, recurrent, disabling depression and should not be treated as a minor version of bipolar I. The strongest maintenance-drug trial evidence often comes from bipolar I populations, so applying a particular result to bipolar II requires attention to the studied sample and outcomes. CANMAT/ISBD provides separate recommendations for bipolar II, and the 2025 treatment guideline discusses lithium, lamotrigine, and quetiapine among its maintenance options.
Cyclothymic disorder and other specified bipolar presentations require their own clinical formulation. Medication decisions cannot be inferred simply from the presence of mood fluctuations. A clinician evaluates whether the episodes meet diagnostic criteria, their duration, severity and consequences, the wider longitudinal pattern, and alternative explanations. General background is available in Types of Bipolar Disorder: Bipolar I, Bipolar II, Cyclothymia, and Other Forms.
How a Maintenance Plan Is Built After an Acute Episode
An effective transition begins with a review of what happened before and during the episode. The care team documents the episode's polarity, duration, severity, mixed or psychotic features, previous relapses, triggers, sleep changes, medication exposures, laboratory concerns, and what brought improvement. The most useful maintenance drug is often one that previously worked and is supported by relapse-prevention evidence for the relevant phase. The 2023 CANMAT/ISBD update advises considering prior response, tolerability, predominant polarity, and comorbid conditions.
Planning includes the possibility of incomplete recovery. Residual depressive symptoms, cognitive complaints, anxiety, insomnia, work impairment, and strained relationships deserve attention even when the person no longer meets criteria for an acute mood episode. A follow-up appointment should address medication effects, access to prescriptions and laboratory testing, psychoeducation, and concrete steps if mood begins to change. These topics form part of NICE long-term management recommendations.
The treatment choice depends on which episodes must be prevented
Preventing mania and preventing bipolar depression are related but distinct goals. Lithium has a broad maintenance evidence base. Lamotrigine is particularly relevant to prevention of depressive recurrence and has substantially weaker evidence for mania prevention when used alone. Several antipsychotics have stronger evidence against manic recurrence than depressive recurrence, although evidence differs by agent and combination. The VA/DoD guideline explicitly issues separate recommendations for the prevention of mania and bipolar depression.
Which Medications Are Used for Bipolar Maintenance?
Medication selection is a medical decision based on diagnosis, history, efficacy for the relevant polarity, risks, interactions, monitoring requirements, and informed preferences. Current guidelines commonly consider lithium, lamotrigine, selected atypical antipsychotics, divalproex/valproate, and certain combinations. Treatment that works for acute mania does not automatically have equally strong evidence for long-term depressive prevention, and an acute bipolar depression medication is not automatically an established lifelong maintenance therapy. The CANMAT/ISBD guidance and 2026 dose-related network meta-analysis illustrate this evidence-based distinction.
Lithium: a major long-term option
Lithium has one of the longest and strongest clinical evidence bases in bipolar maintenance and is recommended by NICE as first-line long-term pharmacological treatment. It can reduce recurrence risk across mood episodes, although no individual receives a guarantee of remaining episode-free. Evidence also suggests an association with reduced suicidal behavior, but estimating how much that benefit applies to an individual requires careful clinical interpretation. Lithium's long-term role is described in the NIMH overview and CANMAT/ISBD update.
Lithium requires serum-level measurement and attention to kidney function, thyroid function, calcium, fluid balance, and interacting drugs. Dehydration, vomiting, severe diarrhea, changes in salt or fluid intake, and medicines such as NSAIDs, some diuretics, and ACE inhibitors can increase lithium exposure and toxicity risk. Severe tremor, confusion, unsteadiness, vomiting, or other concerning symptoms warrant urgent medical assessment. DailyMed prescribing information and NICE lithium monitoring advice explain these risks.
The appropriate serum target and laboratory schedule depend on clinical circumstances. For example, NICE recommends frequent levels during initiation and dose changes, then scheduled levels and renal, thyroid, and calcium monitoring during maintenance, with more frequent tests for higher-risk patients. These figures are clinician-directed monitoring standards rather than instructions to adjust lithium independently. A change in medical condition or a new prescription is a reason to review the plan with the treating team.
Lamotrigine: especially relevant to depressive recurrence
Lamotrigine is an established maintenance option for adults with bipolar I disorder. The VA/DoD 2023 guideline recommends it for prevention of recurrent bipolar depressive episodes but suggests against using lamotrigine alone to prevent mania. This phase-specific distinction is important for a person whose history includes severe mania. Current U.S. prescribing information describes maintenance of bipolar I disorder and states that efficacy for acute manic or mixed episodes has not been established.
Lamotrigine is introduced gradually because of serious rash risk, including Stevens–Johnson syndrome and toxic epidermal necrolysis. Risk rises with certain dosing errors and with concomitant valproate. A new rash, especially with fever, mucosal sores or systemic symptoms, requires prompt clinical assessment according to the drug's warning. Restarting after a gap may require medical re-titration. Hormonal contraception and pregnancy-related changes can also affect lamotrigine exposure, making coordinated medication review important. DailyMed's lamotrigine label provides these safety details.
Valproate/divalproex: clinical efficacy with major safety restrictions
Divalproex and valproate appear among maintenance options in CANMAT/ISBD recommendations, particularly when manic recurrence or mixed presentations are relevant. The strength of evidence for specific long-term depressive outcomes differs across guidelines. U.S. divalproex product labeling identifies treatment of manic episodes as a bipolar indication; a guideline recommendation for maintenance must therefore be distinguished from a product's specific FDA-labeled indication. Choice of this medication demands a careful discussion of alternatives, side effects and reproductive risk.
Valproate can cause severe fetal harm and neurodevelopmental injury after in-utero exposure. It also carries serious warnings for hepatotoxicity and pancreatitis, along with clinically relevant risks such as weight gain, thrombocytopenia, sedation and drug interactions. Baseline and follow-up assessment may include liver tests, blood counts and other tests selected by the clinician. People who are pregnant, may become pregnant, or are planning pregnancy need specialist consultation before a treatment change; abrupt self-discontinuation can also create danger. The 2026 DailyMed divalproex prescribing information and NICE safety recommendations detail these warnings.
Antipsychotic medications and long-acting injectables
Certain second-generation antipsychotics have maintenance evidence. Depending on the agent and clinical circumstances, options include quetiapine, aripiprazole, asenapine, olanzapine and selected long-acting injectable formulations. Some agents are particularly supported for prevention of manic recurrence; quetiapine also has evidence relevant to depressive recurrence. The CANMAT/ISBD maintenance algorithm and VA/DoD phase-specific table should guide interpretation rather than grouping every antipsychotic under a single claim of equivalent effectiveness.
Potential harms include weight gain, altered blood glucose and lipids, sedation, restlessness or akathisia, extrapyramidal symptoms, and occasionally other serious reactions. Monitoring generally includes weight, blood pressure, metabolic measurements, movement symptoms, and medication-specific concerns. Long-acting injections can make regular administration easier for selected patients but require a drug-specific assessment of indication, adverse effects, injection intervals, and patient preference. A long-acting formulation is not evidence that every antipsychotic prevents depressive episodes.
Combination treatment: benefits and treatment burden
For people with severe episodes or recurrence despite an adequate single-agent trial, clinicians may consider combinations such as lithium or divalproex with quetiapine or aripiprazole. Evidence indicates that some combinations reduce recurrence risk relative to a mood stabilizer alone, at the cost of added adverse effects, monitoring and medication burden. The CANMAT/ISBD update discusses newer evidence supporting combinations over follow-up periods extending to 12 months. Continuing an antipsychotic after acute mania should be reviewed periodically rather than maintained indefinitely without renewed benefit–risk evaluation.
Adding a second medication is one possible response to breakthrough episodes. A thoughtful review first evaluates the episode's diagnosis, whether the medication was taken as prescribed, drug interactions, serum concentrations where appropriate, adverse effects, emerging medical problems and coexisting substance use. Additional medication without resolving these factors may increase complexity while leaving the cause of recurrence untouched.
Antidepressants in maintenance: a narrower role
Antidepressant decisions in bipolar disorder depend on subtype, depressive burden, prior antidepressant-associated switching, mixed features, rapid cycling, and accompanying mood-stabilizing treatment. Routine long-term antidepressant use is generally not a core maintenance recommendation, particularly in bipolar I disorder; antidepressant monotherapy is discouraged because it may destabilize mood. Yet research on selected adjunctive antidepressant strategies and bipolar II depression remains heterogeneous. The CANMAT/ISBD 2023 update advises avoiding automatic continuation, while the 2025 clinical guideline discusses individualized exceptions.
The practical principle is an individualized review by the prescriber, including what happened during previous trials and what symptoms recur when medication changes. Neither the presence of depression nor anxiety alone establishes a reason to start or keep an antidepressant indefinitely. Equally, a person who has benefited from a complex regimen should not discontinue it abruptly after reading generalized advice.
What Does the Comparative Evidence Show?
Systematic reviews and network meta-analyses compare treatments across randomized trials and can clarify which options perform better than placebo or particular comparators. They also have limitations: different entry criteria, enriched samples of people who first responded to a drug, varying durations, definitions of recurrence, doses, and tolerability-related dropout. A ranking across all studies is not a personalized recommendation. The 2021 maintenance network meta-analysis identified multiple effective drugs and combinations but also documented variation across comparisons.
A 2026 systematic review and dose-related network meta-analysis evaluated 44 randomized trials involving 10,867 participants and multiple pharmacological strategies. It provides updated comparative evidence, including dose-related analyses, but the drug-and-dose signals should not be read as individualized dose instructions. Population differences, bipolar I versus bipolar II representation, treatment selection and adverse-event patterns can affect estimates. The results are broadly compatible with major guidelines while leaving important comparison questions unresolved.
The 2026 BMJ U-REACH living umbrella review synthesizes evidence across phases and age groups. Its value for maintenance decisions lies partly in asking whether an intervention was actually studied for prevention, which population was represented, and how confidently the outcome can be attributed to treatment. People should expect clinicians to combine these reviews with safety guidance and their own history rather than prescribe according to a league table.
Why protection against mania and depression may differ
A medication can substantially reduce manic recurrence while doing less to prevent depressive recurrence, or the reverse. For example, the VA/DoD recommendations distinguish lamotrigine's depressive-prevention evidence from its limitations as sole protection against mania. This matters for people whose manic episodes involve psychosis or severe impairment, and for those living with repeated prolonged bipolar depression. Treatment often prioritizes the episode type carrying the greatest clinical risk while still monitoring the full mood spectrum. See VA/DoD bipolar guidelines.
How Long Does Bipolar Maintenance Treatment Last?
There is no universal stopping date determined by a number of symptom-free months. Some people remain on treatment for many years, and others receive a carefully reviewed plan reflecting their course, response, medical risks and preferences. Multiple or severe episodes, relapse following earlier discontinuation, and high-consequence episodes generally favor a longer-term prevention strategy. WHO's bipolar disorder fact sheet describes a minimum period of continued care after remission for many adults and longer treatment after repeated episodes; this is a framework for assessment rather than a fixed personal deadline.
Following an acute episode, clinicians consider whether the current medicine has a demonstrated maintenance role, whether short-term adjuncts can eventually be reduced, and what risk would accompany changes. NICE advises discussion of long-term treatment after every episode and recommends reevaluating benefits, adverse effects and monitoring. Long-term treatment should have periodic shared reviews even when no dose changes are necessary. The goal is a regimen that remains both protective and tolerable.
Monitoring: What Should Follow-Up Appointments Cover?
Clinical follow-up addresses more than medication refills. It can assess emerging mania or depression, mixed symptoms, sleep, energy and behavior changes, concentration, work and relationships, suicidal thinking, substance use, physical illnesses, medication effects, practical barriers to care, and whether the relapse-response plan is still usable. The intensity of follow-up should increase around medication changes, recent hospitalization, residual symptoms, pregnancy transitions, and new early warning signs. NICE recommends coordinated physical and psychological monitoring.
Medication-specific laboratory and physical checks
Lithium monitoring involves serum lithium and kidney, thyroid, and calcium assessment; antipsychotic monitoring attends to metabolic and movement-related effects; valproate may require liver and blood-count monitoring and careful reproductive safety review. Lamotrigine monitoring focuses heavily on rash and medication interactions, particularly when titration changes. The exact frequency and testing plan depend on the agent, individual risks, local clinical guidance, and co-prescribed medications. See the official lithium, lamotrigine, and divalproex labels.
Patients can make follow-up more productive by noting side effects, missed doses, sleep disruption, new prescriptions and over-the-counter drugs, unusual thirst or urination, and any significant functional change. Clinicians can explain what each test is for, how results will be communicated, and what symptoms should prompt contact before the next appointment. Making the monitoring plan understandable strengthens shared decision-making.
Psychotherapy and Psychoeducation in Relapse Prevention
Medications form an important part of maintenance treatment, and structured psychosocial support adds skills that pharmacotherapy alone may not provide. Psychoeducation can address early warning signs, medication understanding, sleep regularity, stress and substance use, problem-solving, and family communication. CBT can help with coping patterns and residual depression; family-focused therapy can improve shared responses to warning signs; interpersonal and social rhythm therapy works with routines and interpersonal stress. These are bipolar-specific adjunctive approaches, not interchangeable guarantees. NICE guidance recommends structured relapse-prevention interventions.
A JAMA Psychiatry systematic review and component network meta-analysis assessed 39 randomized trials of adjunctive psychotherapy and found lower recurrence with several structured family, cognitive behavioral, and psychoeducational interventions than with treatment as usual. The magnitude and generalizability vary across programs and follow-up periods. A 2024 randomized trial comparing two group psychotherapy approaches also illustrates that supportive therapeutic components can matter and that treatment may need adaptation for bipolar II.
Family and trusted supporters
With the person's consent, relatives or trusted friends can learn what their usual healthy behavior looks like, what changes commonly preceded past episodes, how to discuss symptoms respectfully, and when urgent clinical review is needed. The aim is cooperative observation and support, not surveillance or treating ordinary disagreement as a symptom. Families may also benefit from discussing boundaries, decision-making during an episode, and their own support needs. NICE recommends family intervention for people in close contact with family as part of longer-term bipolar care.
Sleep, Daily Rhythms, and Behavioral Prevention
Disrupted sleep and circadian schedules can accompany or precede mood instability, especially in people with a history of mania or hypomania. A sustainable routine for sleep and waking, predictable meals, regular physical activity, and manageable activity schedules can support treatment. Shift work, travel across time zones, night-time caregiving, and irregular social schedules deserve practical planning. The NIMH guidance recommends regular routines and mood tracking; interventions such as social rhythm therapy formalize some of these principles.
A sudden reduction in the need for sleep together with elevated energy, unusually rapid speech, impulsivity or expansive plans can be an early signal requiring assessment. Insomnia with fatigue can have many other causes and should be evaluated in context. Sleep monitoring is useful when it helps recognize the person's own pattern, but an app's prediction or single poor night cannot establish a mood episode or clinical relapse.
Alcohol, cannabis, stimulants, and other substances
Substance use can complicate symptoms, sleep, medication adherence, physical safety and diagnostic assessment. The treatment team should ask about alcohol, cannabis, stimulants, prescribed activating medications and other drugs without assuming any single exposure proves the cause of an episode. Where problematic substance use is present, integrated and nonjudgmental care can make a prevention plan more realistic. The VA/DoD guideline addresses comorbidity and ongoing treatment planning.
Early Warning Signs and an Individualized Relapse Plan
A relapse plan identifies the person's earliest reliable changes, the concrete steps that have helped, whom to contact, and which situations require urgent assessment. Warning signs of manic escalation may include progressively shorter sleep, increasing energy, irritability, pressured speech, uncharacteristic spending or risk-taking, and rapid changes in judgment. Warning signs of depression may include sustained loss of interest, slowing, hopelessness, social withdrawal, changes in appetite or sleep, and deteriorating function. Mixed symptoms deserve particular attention because agitation and depressive thinking can coexist. See Early Warning Signs of Mania and Bipolar Relapse.
Plans are most useful when written during relative stability and agreed with clinicians and trusted supporters. They may specify how soon to arrange a review after warning signs emerge, how to protect sleep, how to avoid high-risk commitments, where current medication information is stored, and what emergency contacts are appropriate. A previous episode history often provides more accurate individual signals than a generic checklist. NICE relapse-prevention recommendations emphasize self-monitoring, collaborative relapse plans and practical problem-solving.
What to do after breakthrough symptoms
Symptoms occurring during maintenance treatment call for reassessment rather than an automatic conclusion that the treatment has failed. The clinician first considers whether an acute episode is beginning, whether sleep or substance use has changed, whether a medication was missed, whether laboratory results suggest a problem, and whether another medical or psychiatric condition is contributing. Management might involve more frequent appointments, a medication review, additional psychotherapy, or specialist treatment of an emerging episode. Any changes to prescription regimens should be clinically supervised.
Medication Adherence, Side Effects, and Collaborative Adjustments
Daily adherence can be difficult when a medication causes fatigue, tremor, weight change, sexual side effects, cognitive dulling, or frequent appointments and blood tests. Practical barriers such as pharmacy access, affordability, transportation and irregular schedules matter as well. The care team can consider ways to simplify the regimen, change timing, address side effects, coordinate monitoring, and reassess the benefit–risk balance. CANMAT/ISBD stresses collaborative care and treatment acceptability in maintenance rather than interpreting nonadherence as a character flaw.
Medication changes require special caution. Abruptly stopping lithium can raise recurrence risk, and NICE recommends gradual reduction with close symptom monitoring when lithium discontinuation is clinically chosen. Lamotrigine interrupted for a meaningful period may need a new titration schedule; antidepressants and antipsychotics can also produce discontinuation effects or illness recurrence. Decisions to taper are individualized and supervised. See NICE stopping-lithium guidance and NIMH safety advice.
Pregnancy, Adolescence, and Older Age
Pregnancy planning and the postpartum period
Pregnancy planning is a reason for early joint review between psychiatry and obstetric care, ideally before conception. The risks of relapse and of medication exposure must both be considered. Valproate poses major reproductive hazards; lithium and lamotrigine also require individualized risk assessment and sometimes closer monitoring as physiology changes. The immediate postpartum period can carry elevated risk of severe mood episodes for some people with bipolar disorder. VA/DoD, NICE, and DailyMed valproate labeling provide relevant precautions.
A generic instruction to stop every medication during pregnancy can be dangerous. A safer clinical process considers the person's history of mania or depression, previous postpartum episodes, safer treatment alternatives, monitoring, support at home, and how to respond quickly if symptoms emerge. Medication decisions during pregnancy and breastfeeding require individualized specialist care.
Children and adolescents
Maintenance evidence from adult randomized trials cannot automatically be transferred to younger patients. Bipolar symptoms in young people require careful developmental assessment and evaluation of alternatives. Drug selection and ongoing monitoring must reflect age-specific efficacy and safety evidence, growth and metabolic issues, family participation, and school functioning. The CANMAT/ISBD update gives separate youth recommendations, and NICE outlines multidisciplinary pediatric and adolescent care.
Older adults and medical comorbidity
Older adults may have different renal function, polypharmacy, cardiovascular concerns, cognitive changes, and greater susceptibility to sedation or movement-related adverse effects. Lithium monitoring can require extra attention, and clinicians may favor options previously effective and tolerated while considering comorbidity. Trials specifically in older adults are less plentiful than general adult evidence. The CANMAT/ISBD update discusses the limited older-adult data and clinically relevant maintenance options.
Safety: When More Urgent Help Is Needed
Severe mania, psychosis, rapidly deteriorating judgment, dangerous impulsivity, inability to sleep for prolonged periods with marked activation, or an inability to care for basic needs requires prompt clinical assessment. Suicidal thoughts, intent, or plans require immediate attention according to the situation's urgency. In the United States, call or text 988 for suicide or mental health crisis support; call 911 or use emergency services when there is immediate danger. Outside the United States, contact local emergency or crisis services. NIMH's bipolar guidance includes crisis directions.
Physical danger from medication also needs a separate response. Possible lithium toxicity, a serious lamotrigine rash, severe abdominal pain or other symptoms suggesting valproate pancreatitis, and other severe adverse effects require urgent medical evaluation. Such symptoms should not be dismissed as ordinary changes in mood. Patients and supporters should have clear instructions for reaching the prescriber or emergency service, grounded in the relevant official U.S. drug labels.
What Long-Term Success Looks Like
Maintenance success includes more than the absence of hospitalization. It can mean greater symptom stability, fewer interruptions in employment or education, repaired relationships, tolerable treatment side effects, improved sleep, sustained independence, and better capacity to recognize and respond to warning signs. A person may still experience residual symptoms or occasional episodes while achieving meaningful improvement. The care plan should track outcomes that matter to the individual as well as clinician-rated symptoms. NICE and WHO support an integrated, recovery-oriented approach.
Long-term treatment is an ongoing process of evaluation. What worked following a first episode may need reconsideration after a new medical diagnosis, a serious side effect, an episode of a different polarity, a pregnancy plan, or a change in personal circumstances. Shared decision-making and clearly documented follow-up keep treatment responsive to real life.
Frequently Asked Questions
Can bipolar disorder go into remission without ongoing medication?
Periods without full mood episodes can occur. Their duration and probability vary considerably, and remission alone does not establish that maintenance medication can be safely stopped. The decision depends on diagnosis, prior episode burden, the risks of another episode, response to treatment and adverse effects. Professional guidelines generally support ongoing relapse-prevention care with individualized reviews. NIMH explains why continued treatment is often important.
Is lithium always the best maintenance medication?
Lithium is a leading evidence-based option, and NICE recommends it as first-line long-term treatment. However, tolerability, kidney and thyroid health, reproductive plans, previous response, mood polarity and monitoring feasibility can make other strategies more appropriate. A treatment's average benefit across trials cannot determine the best plan for one individual. See NICE and CANMAT/ISBD.
Is lamotrigine enough to prevent mania?
For a person at meaningful risk of severe manic recurrence, lamotrigine alone may provide inadequate antimanic prevention. VA/DoD recommends it for recurrence of bipolar depression while suggesting against monotherapy for mania prevention. Treatment selection must account for the full history rather than the current mood state. See the VA/DoD guideline.
Can psychotherapy replace mood stabilizers?
Psychotherapy and psychoeducation are valuable evidence-based components of relapse prevention, and may improve coping and functioning. For most people with established bipolar I disorder, they complement rather than replace indicated pharmacological maintenance. Their contribution varies by modality, patient group and outcome. The JAMA Psychiatry systematic review evaluated psychotherapy mainly as an adjunct to medication.
What if a person has another episode despite taking medication?
A breakthrough episode does not mean that every earlier improvement was lost or that the regimen has no protective effect. It warrants timely assessment of diagnosis, polarity, dosing and administration, adherence, adverse effects, interactions, triggers and medical conditions. The team can then consider an evidence-based adjustment, additional supports or treatment for an acute episode. CANMAT/ISBD describes a stepwise approach.
Should antidepressants be continued forever after bipolar depression?
There is no general recommendation that an antidepressant started during bipolar depression must continue indefinitely. Its role depends on the clinical history and response, and on switching or rapid-cycling risks. When a change is considered, the prescribing clinician should develop a safe plan and monitor for recurrence or discontinuation symptoms. See CANMAT/ISBD.
How often should lithium levels and physical health be checked?
Lithium levels are checked more frequently when treatment begins or doses change, then at intervals determined by clinical guidelines and individual risks. Kidney function, thyroid function, calcium and other relevant measures also require monitoring. NICE provides specific minimum schedules and situations demanding increased monitoring, including older age and interacting drugs. A patient's prescriber determines the appropriate plan. NICE lithium guidance is a detailed reference.
Does one night of poor sleep mean a bipolar relapse is starting?
One poor night can occur for many reasons. Concern increases when sleep reduction is sustained and accompanied by changes in energy, activity, mood, judgment or function that resemble an individual's known early episode pattern. Clinicians consider multiple signs over time rather than relying on a single wearable metric. Persistent concerning change should prompt contact with the care team.
Can someone stop maintenance treatment after several stable years?
Treatment can be reevaluated, but the length of remission does not itself establish that abrupt withdrawal is safe. NICE recommends a discussion of risk and gradual, monitored discontinuation if stopping is chosen; it also recommends follow-up after medication cessation. Lithium requires particular caution. Any decision should be made with the prescribing clinician and an explicit relapse-response plan. NICE long-term and discontinuation recommendations provide the framework.
Related Articles
References
Canadian Network for Mood and Anxiety Treatments and International Society for Bipolar Disorders. (2023 evidence update). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. — Full source
DailyMed. (2026). Divalproex sodium delayed-release tablets: Prescribing information. — Full source
DailyMed. (2026). Lamotrigine tablets: Prescribing information and serious skin rash warning. — Full source
DailyMed. Lithium carbonate capsules: Prescribing information. — Full source
De Prisco, M., et al. (2026). Evidence based interventions for bipolar disorder across phases and age groups: U-REACH living umbrella review. BMJ, 394, e100216. — Full source
Fornaro, M., et al. (2026). Efficacy and safety of pharmacological interventions for the maintenance of bipolar disorder: A systematic review and dose-related network meta-analysis across different age groups. Journal of Affective Disorders, 407, 121798. — Full source
Hautzinger, M., and the A2 BipoLife Consortium. (2024). Adjuvant psychotherapies to prevent relapse in bipolar disorder: A randomized clinical trial. JAMA Psychiatry, 81(9), 855–862. — Full source
Kishi, T., et al. (2021). Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: A systematic review and network meta-analysis of randomized controlled trials. — Full source
Menon, V., Ganesh, R., Deep, R., et al. (2026). Clinical practice guidelines for the management of bipolar disorder: 2025 update. Indian Journal of Psychiatry, 68(1), 8–43. — Full source
Miklowitz, D. J., et al. (2021). Adjunctive psychotherapy for bipolar disorder: A systematic review and component network meta-analysis. JAMA Psychiatry. — Full source
National Institute for Health and Care Excellence. (2014; updated 2025). Bipolar disorder: Assessment and management (CG185). — Full source
National Institute of Mental Health. Bipolar disorder: Symptoms, treatment, and long-term management. — Full source
U.S. Department of Veterans Affairs and Department of Defense. (2023). VA/DoD clinical practice guideline for management of bipolar disorder. — Full source
World Health Organization. (2026). Bipolar disorder: Fact sheet. — Full source